Skip to main content

Creative Biolabs Offers Immune Checkpoint-Based Solutions for New Drug Discovery

By: Get News
Creative Biolabs is dedicated to designing the best-fit proposal that screen and discover the desired drug candidates with appropriate functions for worldwide customers, drawing on its extensive experience in drug development and immunological checkpoints.

New York, USA – October 11, 2022 – Researchers from the University of Minnesota and their collaborators at the National Cancer Institute (NCI) recently published findings in Cell Press: Med, revealing that a new checkpoint gene can play a vital role in reducing human T-cell’s ability to recognize and destroy cancer cells, known as CISH. Immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) inhibitors and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) inhibitors, have revolutionized cancer therapeutics during recent years. With prominent achievements in drug development and immune checkpoints, Creative Biolabs is dedicated to providing a range of custom services regarding immune checkpoints to support researcher studies.

As a revolutionary milestone in immuno-oncology, the development of inhibitors for inhibitory immune checkpoints aims to interrupt co-inhibitory signaling pathways, thus enhancing immune responses and promoting immune-mediated elimination of tumor cells. During the past decades, a series of ICIs have been discovered, and the combination therapies that target multiple co-signaling pathways and the tumor microenvironment would further elevate the success rate of cancer treatment. CTLA-4 and PD-1, for example, are associated with co-inhibitory pathways.

“In recent years, immune checkpoint molecules, like CTLA-4 and PD-1, have become powerful tools for preventing immune damage,” a scientist at Creative Biolabs said, “and the immune response of T cells controlled by checkpoint molecules can avoid undesired activation for disease treatments.”

“We’ve also noticed that CTLA-4 molecules have shown an indispensable role in regulating the self-tolerance of autoimmune diseases, the T-cell response of infectious diseases, as well as the anti-tumor activity of various cancers.” added the researcher.

In addition, further clinical data have shown that antibodies targeting PD-1 can reactivate T cells and induce anti-tumor activities to improve patients’ outcomes in the clinic.

With the commitment to being the best immune checkpoint research service provider, Creative Biolabs provides a series of custom services, including but not limited to:

* Custom Immune Checkpoint Protein Development

* Immune Checkpoint Antibody Development

* Immune Checkpoint Targeted Peptide Development

* Immune Checkpoint Targeted Small Molecule Drug Development

* Biomarker Development for Immune Checkpoint Inhibitor

* Immune Checkpoint Assays

* Preclinical Research for Immune Checkpoint Targeting Drugs

To find out more details about immune checkpoint-based solutions at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs offers a full range of immune checkpoint-based solutions for new drug development, including proteins, antibodies, peptides, small-molecule drugs, and inhibitors.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.